API Pramipexole Hydrochloride Factory Pramipexole HCl

• Customization: Available
• Powder: Yes
• Customized: Negotiable
• Model NO.: QS-Pramipexole Hydrochloride
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Power
• Product Name: Pramipexole Hydrochloride
• CAS No.: 104632-26-0
• Molecular Formula: C10h17n3s
• Molecular Weight: 211.33
• Appearance: White to off-White Crystalline Powder
• Identification (HPLC): Retention Time Matches Reference Standard
• Purity (HPLC): 98.0% - 102.0%
• Water Content (Kf): ≤ 1.0% W/W
• Residual Solvents: Complies with Ich Q3c Limits
• Heavy Metals (Pb, as, CD): ≤ 20 Ppm
• Sulphated Ash: ≤ 0.1%
• pH: 4.5 - 6.5
• Chromatographic Purity: Main Peak ≥ 99.0%
• Injection Volume: 10 µl
• Specific: COA
• Transport Package: Negotiable
• Specification: >99%
• Trademark: QS
• Origin: Xian
• Production Capacity: 1500kg/Month

Product Description

API Pramipexole Hydrochloride Factory Pramipexole HCL

Product Description

Product Details

Product Name	Pramipexole Hydrochloride
Appearance	White to off-white crystalline powder
Assay	99%
MF	C10H17N3S
MW	211.33

Pramipexole hydrochloride is a selective non ergot dopamine receptor agonist used to treat Parkinson's disease. It was developed by Boehringer Ingelheim in Germany and is currently the largest prescription dopamine receptor agonist in the world. In May 1997, it was first approved by the US FDA for the treatment of idiopathic Parkinson's disease, which can alleviate patients' symptoms and signs. It can be used alone or in combination with levodopa. The trade name Mirapex, which is marketed in the US, is the first FDA approved drug for Parkinson's disease in the past six years

Application&Function

Pramipexole Hydrochloride (CAS 104632-26-0) is a dopamine receptor agonist primarily used for the following purposes:
role
treat Parkinson's disease
By selectively activating dopamine D2 and D3 receptors in the brain, supplementing dopamine function and improving movement disorders such as tremors, stiffness, and bradykinesia, it is particularly suitable for early and late stage Parkinson's disease patients.
Treatment for Restless Leg Syndrome (RLS)
Relieve lower limb discomfort and motor impulses caused by RLS, usually used for moderate to severe cases.
common side-effects
Including nausea, dizziness, drowsiness, low blood pressure, etc., long-term use may cause impulse control disorders (such as pathological gambling, overeating, etc.).
precautions
The dosage needs to be gradually adjusted to avoid adverse reactions.
Pregnant and lactating women, as well as patients with severe cardiovascular disease, should use with caution.

Specification

ABOUT US